Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 6/20 | 0.50 |
| ▸ | ITGA4 | P13612 | 6/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6131662 | 1.00 | ITGB1 (0.50) | ITGB1ITGA4CA2ALDH1A1LMNA | |
| SCHEMBL6532346 | 0.87 | ITGB1 (0.41) | ITGB1ITGA4ALDH1A1LMNAMAPT | |
| SCHEMBL4734791 | 0.85 | ITGB1 (0.55) | ITGB1ITGA4LMNAPPARG | |
| SCHEMBL6131675 | 0.77 | MAPT (0.37) | ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL6131693 | 0.76 | L3MBTL1 (0.36) | ITGB1ITGA4CA2ALDH1A1LMNA | |
| SCHEMBL6131689 | 0.76 | L3MBTL1 (0.36) | ITGA4MAPTMEN1KMT2A | |
| SCHEMBL2983988 | 0.75 | ITGB1 (0.61) | ITGB1ITGA4 | |
| SCHEMBL2983609 | 0.74 | ITGB1 (0.49) | ITGB1ITGA4 | |
| SCHEMBL2984859 | 0.74 | ITGB1 (0.63) | ITGB1ITGA4 | |
| SCHEMBL2988053 | 0.74 | ITGB1 (0.63) | ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951943-B2 | Process for the preparation of phenylalanine enamide derivatives | CELLTECH R & D LIMITED (GB) | 2005-10-04 | — | — | US | disclosed |
| US-20040073033-A1 | Process for the preparation of phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073033-A1 | Process for the preparation of phenylalanine enamide derivatives | NPY2R, NPY1R, NPR1 | ITGB1 4148/4885ITGA4 3960/4885CA2 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.